Nosso grupo organiza mais de 3.000 Séries de conferências Eventos todos os anos nos EUA, Europa e outros países. Ásia com o apoio de mais 1.000 Sociedades e publica mais de 700 Acesso aberto Periódicos que contém mais de 50.000 personalidades eminentes, cientistas de renome como membros do conselho editorial.
Periódicos de acesso aberto ganhando mais leitores e citações
700 periódicos e 15 milhões de leitores Cada periódico está obtendo mais de 25.000 leitores
Hattersley Larralde
Drug resistance has emerged as a formidable challenge in modern healthcare, posing significant threats to the effectiveness of treatments across various medical disciplines. This paper examines the multifaceted problem of drug resistance, encompassing its molecular mechanisms, epidemiological factors, and clinical implications. We delve into the pivotal role of microbial organisms, such as bacteria and viruses, in driving antibiotic and antiviral resistance, as well as the genetic and adaptive processes that underlie this phenomenon. Furthermore, we explore how drug resistance extends beyond infectious diseases to encompass cancer and other non-communicable diseases, complicating therapeutic strategies. The socio-economic dimensions of drug resistance are also considered, highlighting the economic burdens and healthcare disparities it engenders. In response, this paper proposes a comprehensive approach involving enhanced surveillance, novel drug development, optimized treatment protocols, and public education. By rising to the challenge of drug resistance, the modern healthcare landscape can safeguard the efficacy of existing treatments and ensure better health outcomes for patients worldwide.